Expanded Highly Active Antiretroviral Therapy Coverage - A Powerful Strategy to Curb Progression to AIDS, Death and New Infections.
Sustained combination of HIV prevention strategies is essential to curb the spread of the HIV/AIDS epidemic. The use of highly active antiretroviral therapy (HAART) decreases morbidity and mortality, as well as HIV transmission, among treated individuals. The concept of 'treatment as prevention' is dependent on HAART's ability to sustain HIV-1 RNA virological suppression at the individual and population levels, and has been demonstrated in studies evaluating transmission in mother-to-child, sero-discordant couples and large treated populations. The worldwide expansion of maximally effective antiretroviral drug regimens has been coupled with concerns regarding the magnitude of the financial investment required. However, HAART's compounding effect on reduced morbidity, mortality and transmission makes the expansion of HAART coverage highly cost-averting. Building on a mathematical model that evaluated the impact of expanded HAART access on viral load in a Canadian setting, we demonstrate that an investment of CA$249 million over the lifetime of treated individuals would result in a net gain of CA$2.1 billion over 30 years. This provides a powerful economic incentive to rapidly scale up HAART access worldwide.
British Columbia Centre for Excellence in HIV/AIDS, St Paul's Hospital.
Aranka
A
Anema
Viviane D
VD
Lima
Karissa
K
Johnston
Adrian
A
Levy
Julio Sg
JS
Montaner
JAMA. 2008 Aug 6;300(5):555-70
18677028
JAMA. 2000 Mar 1;283(9):1175-82
10703780
J Infect Dis. 2008 Jul 1;198(1):59-67
18498241
J Infect Dis. 2004 Sep 1;190(5):879-85
15295691
JAMA. 1996 Feb 28;275(8):599-605
8594240
Nat Rev Microbiol. 2004 Jan;2(1):33-42
15035007
Disaster Med Public Health Prep. 2008 Oct;2(3):150-65
18677271
MMWR Recomm Rep. 2005 Sep 30;54(RR-9):1-17
16195697
AIDS. 1997 Aug;11(10):1249-54
9256943
AIDS. 2000 Mar 10;14(4):415-21
10770544
CMAJ. 2008 Jul 1;179(1):13-4
18591515
J Acquir Immune Defic Syndr. 2006 Apr 15;41(5):632-41
16652038
J Infect Dis. 2005 May 1;191(9):1403-9
15809897
Lancet. 2008 Jul 26;372(9635):270-1
18657692
Lancet. 2008 Aug 23;372(9639):669-84
18687459
Proc Natl Acad Sci U S A. 1995 Dec 19;92(26):12100-4
8618852
J Infect Dis. 2007 Apr 1;195(7):951-9
17330784
J Acquir Immune Defic Syndr. 2006 Dec 1;43(4):451-7
16980906
J Acquir Immune Defic Syndr. 2001 Jun 1;27(2):209
11404544
Ann Intern Med. 2007 Apr 17;146(8):591-601
17438318
Lancet. 2009 Jan 3;373(9657):48-57
19038438
J Infect Dis. 2008 Sep 1;198(5):687-93
18662132
AIDS. 1998 Apr 16;12(6):597-604
9583599
Nature. 2007 Sep 27;449(7161):390
17898737
J Acquir Immune Defic Syndr. 2002 Mar 1;29(3):275-83
11873077
Curr Infect Dis Rep. 2008 Jul;10(4):323-31
18765106
Lancet. 2006 Aug 5;368(9534):531-6
16890841
N Engl J Med. 2000 Mar 30;342(13):921-9
10738050
J Acquir Immune Defic Syndr. 2005 Sep 1;40(1):96-101
16123689